Periprosthetic infection treatment target and application thereof

• Main Authors: PAN BAIQI, SHENG PUYI, LONG LINGLI, WU XIAOYU
• Format: Patent
• Language: Chinese; English
• Published: 04.06.2024
• Subjects: AGRICULTURE; ANIMAL HUSBANDRY; BEER; BIOCHEMISTRY; CARE OF BIRDS, FISHES, INSECTS; CHEMISTRY; COMPOSITIONS OR TEST PAPERS THEREFOR; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES; ENZYMOLOGY; FISHING; FORESTRY; HUMAN NECESSITIES; HUNTING; HYGIENE; INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES; MEASURING; MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MUTATION OR GENETIC ENGINEERING; NEW BREEDS OF ANIMALS; PHYSICS; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROCESSES OF PREPARING SUCH COMPOSITIONS; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; TESTING; TRAPPING; VINEGAR; WINE

The invention belongs to the technical field of biomedicine, particularly discloses a periprosthetic infection treatment target and application thereof, and particularly discloses application of an antagonist or an expression inhibitor aiming at Treg cell immune checkpoint molecules in any one of the following aspects: preparing a product for preventing, treating, relieving or improving periprosthetic infection; preparing a product for inhibiting occurrence and development of periprosthetic infection; preparing a product for inhibiting proliferation and/or growth of periprosthetic infected tissue cells; preparing a product for promoting or inducing apoptosis of periprosthetic infected tissue cells; preparing a product for inhibiting inflammation, necrosis or fibrosis of periprosthetic infected tissues; the immune checkpoint molecule is CTLA4 and/or CXCR6, and by carrying out target CXCR6 knockout on Treg and using anti-CTLA4, it is found that a product targeting CTLA4 and/or CXCR6 has a potential therapeutic